Rani & ProGen have partnered to co-develop & commercialize RT-114 (ProGen’s PG-102 contained in RaniPill capsule) for obesity
Both of them will share global development & commercialization of RT-114, with a 50/50 cost & revenue split. Rani will conduct preclinical & P-I study (starting in 2025) plus gain exclusive rights in the US, EU, Canada & Australia with ProGen covering ROW. Upfront financial exchange is not involved
In addition, PG-102 (GLP-1/GLP-2 dual agonist) showed a good safety profile with fewer GI side effects vs other programs under its P-I trial (Korea). PK/PD data & preclinical results further suggest weekly to monthly dosing of RT-114, improving patient adherence
Ref: Rani Therapeutics | Image: Rani Therapeutics
Related News:- Rani Therapeutics Reports the Results for RT-111 Capsules Containing CT-P43 (biosimilar, ustekinumab) in P-I Trial for the Treatment of Various Indications
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
